Effects of gene polymorphism on efficacy and toxic effect of chemotherapy regimen containing oxaliplatin in stage Ⅲ and Ⅳ colorectal cancer
OBJECTIVE To investigate the effects of GSTP1,XRCC1,ABCB1,MTHFR gene polymorphisms on efficacy and toxic effect of chemotherapy regimen containing oxaliplatin in patients with stage Ⅲ and Ⅳ colorectal cancer patients.METHODS Clinical data of 76 patients with stage Ⅲ and Ⅳ colorectal cancer who received chemotherapy regimen containing oxaliplatin(XELOX,FOLFOX)were collected from the Second Affiliated Hospital of Soochow University from September 2018 to March 2020.The correlation of genotypes with progression-free survival(PFS)and toxic effect was analyzed by using univariate and multivariate COX regression model.RESULTS Carriers of the ABCB1 3435T＞C locus C allele(TC/CC)had a significantly higher risk of progression compared to TT genotype patients[HR=2.39,95%CI(1.05,5.50),P=0.038].The risk of progression in patients at stage Ⅳ was significantly higher than those at stage Ⅲ[HR=8.11,95%CI(3.39,19.40),P＜0.001].Chemotherapy regimen,Karnofsky performance status score and tumor site had no significant effect on disease progression(P＞0.05).Mutations in gene loci were not correlated with adverse reactions(P＞0.05).CONCLUSIONS Patients carrying ABCB1 TC/CC and receiving chemotherapy regimen containing oxaliplatin have a higher risk of disease progression,which may be associated with longer PFS in patients(TT genotype)with stage Ⅳ colorectal cancer receiving the chemotherapy,while GSTP1,XRCC1,and MTHFR gene polymorphisms have no significant impact.
万方数据
维普
